Estimating the budget impact of orphan drugs in Sweden and France 2013–2020 by Hutchings, Adam et al.
  
 
 
 
warwick.ac.uk/lib-publications 
 
 
 
 
 
Original citation: 
Hutchings, Adam, Schey, Carina, Dutton, Richard, Achana, Felix A. and Antonov, Karolina. 
(2014) Estimating the budget impact of orphan drugs in Sweden and France 2013–2020. 
Orphanet Journal of Rare Diseases, 9 (1). p. 22. 
 
Permanent WRAP URL: 
http://wrap.warwick.ac.uk/78539  
       
Copyright and reuse: 
The Warwick Research Archive Portal (WRAP) makes this work of researchers of the 
University of Warwick available open access under the following conditions. 
 
This article is made available under the Creative Commons Attribution 2.0 Generic (CC BY 
2.0) license and may be reused according to the conditions of the license.  For more details 
see: http://creativecommons.org/licenses/by/2.0/ 
 
A note on versions: 
The version presented in WRAP is the published version, or, version of record, and may be 
cited as it appears here. 
 
For more information, please contact the WRAP Team at: wrap@warwick.ac.uk 
 
RESEARCH Open Access
Estimating the budget impact of orphan drugs in
Sweden and France 2013–2020
Adam Hutchings1*, Carina Schey2, Richard Dutton3, Felix Achana4 and Karolina Antonov5
Abstract
Background: The growth in expenditure on orphan medicinal products (OMP) across Europe has been identified
as a concern. Estimates of future expenditure in Europe have suggested that OMPs could account for a significant
proportion of total pharmaceutical expenditure in some countries, but few of these forecasts have been well
validated. This analysis aims to establish a robust forecast of the future budget impact of OMPs on the healthcare
systems in Sweden and France.
Methods: A dynamic forecasting model was created to estimate the budget impact of OMPs in Sweden and France
between 2013 and 2020. The model used historical data on OMP designation and approval rates to predict the number
of new OMPs coming to the market. Average OMP sales were estimated for each year post-launch by regression analysis
of historical sales data. Total forecast sales were compared with expected sales of all pharmaceuticals in each country to
quantify the relative budget impact.
Results: The model predicts that by 2020, 152 OMPs will have marketing authorization in Europe. The base case OMP
budget impacts are forecast to grow from 2.7% in Sweden and 3.2% in France of total drug expenditure in 2013 to
4.1% in Sweden and 4.9% in France by 2020. The principal driver of expenditure growth is the number of new OMPs
obtaining OMP designation. This is tempered by the slowing success rate for new approvals and the loss of intellectual
property protection on existing orphan medicines. Given the forward-looking nature of the analysis, uncertainty exists
around model parameters and sensitivity analysis found peak year budget impact varying between 2% and 11%.
Conclusion: The budget impact of OMPs in Sweden and France is likely to remain sustainable over time and a relatively
small proportion of total pharmaceutical expenditure. This forecast could be affected by changes in the success rate for
OMP approvals, average cost of OMPs, and the type of companies developing OMPs.
Keywords: Orphan medicines, Budget impact, Health economics, Europe
Background
Rare diseases are life-threatening or severely debilitating
conditions that affect very small patient populations. It
is estimated that 6,000 to 8,000 rare diseases affect
approximately 30 million people in the European Union
(EU) [1]. Rare diseases, as defined according to the
European Orphan Medicinal Product (OMP) Regulation,
affect no more than five in 10,000 individuals [2].
The OMP Regulation was adopted in 1999 and came
into force in 2000 with the aim of establishing regulatory
pathways and incentives for companies to develop treat-
ments for life-threatening or chronically debilitating
conditions. Overall, the OMP Regulation has been per-
ceived to be a great success [3]. Prior to the Regulation,
very few treatments were available for rare diseases,
whereas in December 2012, 878 drugs had received an
OMP designation, including 78 drugs with a marketing
authorization in the EU [4].
After the introduction of the OMP Regulation in Europe,
and since the approval of the first OMPs, health policy
makers and payers have raised concerns about their cost,
both at a patient level and in aggregate across diseases
[5,6]. Concerns about the pricing, affordability and cost-
effectiveness of OMPs have led to calls to revisit the incen-
tives laid out in the OMP Regulation, and to adopt more
stringent pricing and reimbursement policies for OMPs
[7]. For instance, the Dutch Health Care Insurance Board
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(CVZ) has questioned whether it is reasonable to reim-
burse drugs for rare lysosomal storage disorders due to
concerns about cost effectiveness [8].
Several studies conducted in European countries have
estimated the market availability or budget impact of
OMPs in different settings [9,10]. A study observed that
there was substantial variation in the market uptake of
OMPs across the 23 countries included in the analysis.
The gross domestic product and the availability of a for-
mal health technology assessment organization within
each country proved to be key determinants in the up-
take of OMPs [11]. Because the decision to fund specific
OMPs is within the remit of each country, access to ap-
proved OMPs varies greatly across Europe [12]. An ana-
lysis of OMP budget impact in five European countries
in 2007 found the total pharmaceutical expenditure on
existing OMPs is very low in Europe (1.0–2.1%, depend-
ing on the country) [10]. A previous study by the au-
thors estimated the average annual cost of OMPs per
patient to predict the total cost of orphan medicines in
Europe between 2010 and 2020 as a percentage of total
European pharmaceutical expenditure, and concluded
that concerns of spiraling OMP expenditure were not
justified [13].
Although these studies inform on interesting aspects
of OMPs, they are general in their approach and mainly
report retrospective data. In order to address concerns
that the development of new OMPs could affect future
healthcare budgets, analyses incorporating rigorous
methodology are warranted. To date, the OMP markets
of Sweden and France have not been thoroughly analyzed
as stand-alone markets. OMP expenditure in these two
countries was investigated in this study because Sweden
and France respectively are considered to be at the re-
strictive and permissive ends of the spectrum with regards
to OMP accessibility and reimbursement [14-16].
This study developed a dynamic forecasting model to
examine historical trends in OMP designation, market
authorization, sales, and budget impact in these two
markets, from 2000 to 2012. These historical data were
then used to predict the evolution in OMP use for exist-
ing diseases and new indications between 2013 and
2020, with a view to estimating their budget impact on
the national pharmaceutical market. The analysis estab-
lishes a robust forecast of the future budget impact of
OMPs on the French and Swedish healthcare systems.
Methods
For the period 2000–2012, the OMP budget impact was
calculated for each country based on the observed sales of
authorized OMPs as a percentage of total pharmaceutical
industry sales [17,18]. To estimate the corresponding
budget impact for the 2013–2020 period, a dynamic fore-
casting model encompassing four sub-analyses was cre-
ated (Figure 1).
Sub-analysis 1. Estimated number of approved OMPs in
the period 2013–2020
The number of new OMP marketing authorization ap-
provals was predicted by applying a time-dependent
Figure 1 OMP budget impact forecast model structure (2013–2020).
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‘success rate’ factor to the pool of designated OMPs that
are currently unauthorized, which may potentially be au-
thorized as OMPs in the future.
New OMP designations for the period 2013 – 2020
were estimated based upon a linear regression of histor-
ical designation rates per year since the introduction of
the OMP Regulation. The predicted new OMP designa-
tions were added to those OMPs already designated
in a time-dependent matrix that specified the ‘age’
(years since designation) of each drug at each year in
the model. The number of designated OMPs with ap-
proved market authorization was estimated using an
age-dependent success rate factor calculated for each year
following OMP designation, based on an analysis of all
OMPs designated and approved in Europe since 2000 [4].
Each designated OMP’s lifecycle was analyzed, noting its
status in each year since designation (Pending Approval,
Approved, Withdrawn). An age-specific success rate was
calculated across the whole sample for each year following
OMP designation. With this methodology, the issue of lag
times between designation and approval was accounted
for in the analysis. As well as new drugs achieving OMP
designation, drugs with an existing designation can have
that status withdrawn, possibly because the drug failed
during clinical development, was developed for a non-
orphan indication or for commercial reasons. To account
for this, a similar distribution was estimated to predict the
likelihood of a designated OMP being withdrawn from the
designation list at each year since designation.
The analysis was then conducted on different time pe-
riods to determine if the success rate was constant over
time. In order to select the appropriate distribution to
predict the success rate from 2013 onwards, an identical
analysis was undertaken on orphan drug data from the
United States (US) [19], to corroborate any temporal
trends seen in Europe, since orphan drug legislation was
introduced in the US as early as 1983 [20].
Sub-analysis 2. Expected average sales per year since
launch per OMP
To calculate the average sales per year since launch for
an OMP in Sweden and France, sales data of all OMP
authorized in Europe since 2000 were analyzed separ-
ately for each market. Sales data for these OMPs in each
country were obtained for 2000–2012 [17,18] and quan-
tified by year post-launch. A regression analysis esti-
mated the average sales for each year post-launch across
all OMPs. The regression model was fitted in WinBUGS
[21]. The model specified the relationship between
mean sales and year post-launch taking into account
correlations between year-on-year sales for the same
OMP (within drug variance), between sales of different
OMPs (between drug variance), and between mean sales
and time effects (random slopes and intercepts). Several
models were fitted, with best fit being determined using
the Deviance Information Criterion (DIC). The model
with the lowest DIC was judged to be the best fit. Based
on the DIC, the best fitting model was a random inter-
cept and slope model with log (year) and year-squared
as time-dependent variables.
The effect of loss of intellectual property protection
(IPP) for OMPs was built into the forecast by adjusting
each OMP average annual sales. A patent lawyer ana-
lyzed patents and marketing exclusivity rights of OMPs
marketed in Europe [22]. The most extensive form of
IPP (patent, supplementary patent, marketing exclusiv-
ity) was used for each OMP. The average duration of
IPP was 12 years. The average sales were adjusted within
the model to reflect the expected price change at loss of
IPP. Price cuts of 65% and 60% were applied on loss of
IPP in Sweden and France, respectively, based on
market-specific price dynamics [23,24].
Sub-analysis 3. Predicted total individual pharmaceutical
market value (for Sweden and France)
In order to provide a relative estimate of the OMP
budget impact, it was necessary to predict the total
pharmaceutical market growth rate for each country
until 2020. This was estimated using Intercontinental
Medical Statistics (IMS), Groupement pour l’Elaboration
et la Réalisation de Statistiques (GERS) sales data for
France, and Apotekets Inköps Pris (AIP) pharmacy-in
prices for Sweden to ensure alignment with the OMP
market estimate from 2000–2012 [17,18,25].
Sub-analysis 4. Predicting the budget impact of OMPs
2013–2020
Results from Sub-analysis 1 (number of OMPs receiving
marketing authorization each year, and age of OMP at
that time point) and Sub-analysis 2 (average expected
sales for an OMP at given age) were combined to esti-
mate the total sales of OMPs from 2013 through to
2020. The relative budget impact was reached by divid-
ing this gross estimate by the predicted total pharma-
ceutical market value in both markets over the same
period (Sub-analysis 3).
Sensitivity analyses were undertaken on key factors in
the model to test parameter uncertainty: change in price
at loss of IPP, predicted market growth rate, success rate
for designated OMPs obtaining marketing authorization
approval, predicted growth in new OMP designations,
and average total OMP sales post-launch.
Results
Estimated number of approved OMPs in the period
2013–2020
The model predicts that by 2020, 152 OMPs will have mar-
keting authorization in Europe (Figure 2). The predicted
Hutchings et al. Orphanet Journal of Rare Diseases 2014, 9:22 Page 3 of 9
http://www.ojrd.com/content/9/1/22
annual growth rate is higher than the observed trend over
the last five years, reflecting the growing OMP designation
rate (Figure 3).
While over 1,000 drugs have received OMP designa-
tion in Europe since 2000 [26], not all of these drugs
have retained this status. The OMP designation of some
drugs has been withdrawn, often because the drug
development program has failed. In December 2012,
878 drugs currently had OMP designation in Europe, of
which only 78 (8.8%) had obtained market authorization
[4]. Manufacturers continuously apply to add New Chem-
ical Entities to the list of designated OMPs, and the num-
ber of OMP designations has grown consistently since the
introduction of the OMP Regulation in 2000, from 15 new
designations in Europe per year in 2000 to 116 in 2012. A
linear regression model (R2 = 0.79) fitted to the observed
(measured) data predicted that there would be 146 new
OMP designations per year by 2020 (Figure 3).
The annual success and failure probabilities by OMP
age show that the chances of successful market autho-
rization are low and constant over time, with the majority
of successful drugs being approved between 2 and 7 years
post designation (Figure 4). Since the introduction of the
OMP Regulation, a trend towards lower market approval
success rates over time was observed (Figure 5). The high-
est market approval success probabilities were recorded
between 2000–2005 and the lowest between 2008 – 2012.
(The lower success rates in more recent years do not re-
flect a lack of maturity in this data, as the success rates
were calculated by dividing the number of approved drugs
by the number of designated drugs of the same age during
that period, not the number of designated products in the
year of approval). Across all four time periods analyzed,
the success rates all dropped around seven years following
OMP designation. The analysis conducted on orphan
drug data from the US [19] revealed a similar trend,
whereby success rates fell in each consecutive decade
from 1983 to 2012. Because of the age-specific nature of
this analysis – accounting for time lags between desig-
nation and approval – this approach provides a more
accurate estimate of success rates than simple ratios of
approvals to designations within an individual year. Ac-
cordingly, the success distribution rate for the most re-
cent European data (2008–2012) was felt to be the most
likely approximation of future success rates in Europe,
and the one that was used in the model to estimate the
number of designated OMPs that would achieve mar-
keting approval in future years.
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Figure 2 OMPs with marketing authorization in Europe: observed and predicted data.
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Figure 3 Observed and predicted new OMP designations per year in Europe.
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Expected average sales per year since launch per OMP
According to the regression analysis, the modeled aver-
age OMP sales per year since 2000 grew at similar rates
in both countries analyzed, up to seven years post-
launch, after which sales progressed more slowly in
France compared with Sweden (Figure 6). In the first
four years post-launch, average sales grew to SEK 11.1
million in Sweden and EUR 13.4 million in France, and
then the growth rate steadied, respectively reaching
SEK 21.5 million in Sweden and EUR 21.6 million in
France in year 12 post-launch. This reflects the rela-
tively low sales that OMPs usually obtain, with the
exception of a few high-cost OMPs such as imatinib.
In France 64% of OMPs have sales of less than EUR
10 million [17,18].
Predicted total individual pharmaceutical market value
Overall, during the 2000–2012 period, the Swedish
pharmaceutical market grew from SEK 20.3 billion to
SEK 36.8 billion [17], an average annual growth rate of
4.0%. During this period, the average annual growth rate
for France was 3.0% (from EUR 20.5 billion to EUR 34.0
billion) [18]. Relatively quick growth was observed up to
2007 (4.0–5.0%), after which pharmaceutical market
growth rates slowed following the 2008 economic crisis.
The Swedish market grew modestly between 2008 and
2010, and fell slightly in 2012. Similarly, the French
market slowed down between 2010 and 2012. Both
countries were modeled forward from 2013 using a 2.0%
per annum growth assumption (Figure 7), which the au-
thors felt was a conservative estimate, representing a
mid-point between the long-term growth rate over the
last 12 years and the market stagnation seen after the
2008 economic crisis.
Predicted budget impact of OMPs 2013–2020
The observed OMP budget impact in Sweden grew at a
steady rate following the introduction of the OMP Regu-
lation, reaching 0.7% of total drug sales in 2006. The
budget impact growth rate accelerated between 2006
and 2009, then slowed more recently, reaching 2.5% of
total pharmaceutical market value in 2012. The observed
budget impact growth rate in France followed a similar
trajectory to Sweden, although showing a more pro-
nounced slowing in budget impact growth since 2008,
with budget impact appearing to fall slightly in 2012 to
3.1% of total pharmaceutical sales (Figure 8). The model
predicted that between 2013–2020 OMP budget impact
will grow at a steady rate from 2.7% in Sweden and 3.2%
in France in 2013 to 3.9% and 4.6% respectively by 2018,
after which OMP sales will plateau at 4.1% in Sweden
and 4.9% in France of the total pharmaceutical market
(Figure 8).
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Figure 4 Annual market approval rates for designated OMPs in Europe.
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Sensitivity analysis
Because the predicted data are not simple extrapolations
of observed data, but rather a modeled prediction in-
corporating additional information, sensitivity analyses
were carried out (Table 1).
There is considerable uncertainty around the likely im-
pact of loss of IPP on prices of OMP in future. Accord-
ingly the budget impact was assessed assuming that there
were to be no change in OMP price at the point of loss of
IPP. In this scenario peak year budget impact reaches
5.7% and 6.4% of total pharmaceutical sales in Sweden
and France, respectively. The trajectory of the modeled
data under this scenario almost superimposes that of the
forecasted cumulative market authorizations (Figure 2).
It was also felt to be important to understand the im-
pact of a change in the average cost per year of OMPs. If
the average cost per year increased by 50% in future, the
peak year budget impact reaches 8.1% and 9.9% of total
pharmaceutical sales in Sweden and France, respectively.
Sensitivity analyses further explored the estimated
growth rate of the two pharmaceutical markets through to
2020, the success rates for designated OMPs achieving
marketing authorization approval, and growth in new
designations per year from 2013. Of these only the success
rate change had a material impact on the prediction.
When the predicted success rate is that observed in the
first five years following OMP Regulation the peak year
budget impact is 9% in Sweden and 11% in France.
Discussion
Because approximately 30 million individuals are affected
by rare diseases in the EU [1], the Orphan Medicinal
Products Regulation implemented in 2000 recognized the
unmet need for rare disease treatments, and implemented
incentives for companies to develop treatments for these
diseases. The price of individual OMPs and the growth of
aggregate OMP expenditure across Europe has since been
raised as a cause for concern by payers and health policy
makers. However, concerns about budget impact may be
misguided, and based on forecasts that are predicated on
assumptions that high rates of OMP designation will lead
to equally high levels of OMP approvals.
Results from this robust analysis estimate that the fu-
ture budget impact of OMPs in France and Sweden will
be sustainable, with peak budget impacts amounting to
4–5% of the total pharmaceutical expenditure by 2020.
Figure 6 Modeled average OMP sales by year post-launch in France and Sweden.
Figure 7 Pharmaceutical market growth. French and Swedish data are each observed for 2000–2012 [17,18]. Both countries are modeled
forward from 2013 using a 2% per annum growth assumption.
Hutchings et al. Orphanet Journal of Rare Diseases 2014, 9:22 Page 6 of 9
http://www.ojrd.com/content/9/1/22
The budget impact is predicted to slow from 2018 on-
wards, as OMP growth rates converge with those of the
overall pharmaceutical market.
There are two reasons why budget impact is expected
to slow despite continued growth of OMP designations:
first, the low market approval success rate for OMPs
(Figure 4), and second, the savings from existing prod-
ucts losing IPP and being replaced by generic versions.
The success rates for OMP authorizations in Europe are
unlikely to return to those levels reached in the early years
post-Regulation, as per the worst-case scenario explored
in sensitivity analysis. Early success rates in Europe were
inflated by manufacturers of OMPs already available in
the US taking advantage of newly introduced EU legisla-
tion to obtain approvals in Europe. European OMP
authorization rates have since fallen (Figures 4, 5), reflect-
ing trends in US orphan drug approval since 1983 [19]. It
is more likely that future success rates will be lower than
those used in our model. The scenario of 50% increase in
average OMPs sales per year would represent a significant
departure from the observed evidence to date.
A previous study undertaken by EURORDIS in 2009
also attempted to forecast the number of new OMPs to
be approved in Europe [27]. Under the ‘optimistic’
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Figure 8 OMP budget impact as percentage of total pharmaceutical market: observed and predicted data.
Table 1 Results from one-way sensitivity analyses on key model parameters
Parameter Value*
Peak year budget impact as% of
total pharmaceutical spend (year)
Peak year budget impact as% of
total pharmaceutical spend (year)
Sweden France
1 Change in price at loss of IPP Base -65% (SE) 4.1% (2020) 4.9% (2020)
-60% (FR)
Best -80% 3.8% (2020) 4.4% (2020)
Worst 0% 5.7% (2020) 6.4% (2020)
2 Pharmaceutical annual market growth
rate 2012–2020
Base 2% 4.1% (2020) 4.9% (2020)
Best 4% 3.4% (2018) 4.2% (2020)
Worst 0% 4.9% (2020) 5.8% (2020)
3 Success rate for designated OMPs
obtaining market authorization
approval
Base Observed trend
rate 2008–2012
4.1% (2020) 4.9% (2020)
Best 50% of base
case rate
3.3% (2017) 3.9% (2017)
Worst Observed trend
rate 2000–2005
9.0% 11.0% (2020)
4 Annual growth in new OMP
designations from 2012
Base y = 5.7418x - 11452 4.1% (2020) 4.9% (2020)
Best 50% < base 4.0% (2020) 4.8% (2020)
Worst 50% > base 4.2% (2020) 5.0% (2020)
5 Average total annual sales of an OMP
post-launch (year 1 – year12)
Base As per Figure 6 4.1% (2020) 4.9% (2020)
Best -50% p. a. 2.0% (2020) 2.5% (2020)
Worst +50% p. a. 8.1% (2020) 9.9% (2020)
*‘Best’ and ‘worst’ cases are from the perspective of funders of OMPs, with ‘best’ representing the lower budget impact and ‘worst’ the higher.
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scenario (higher number of approved OMPs) the authors
predicted that there would be more than 200 approved
OMPs by 2020, against 152 predicted in this study. How-
ever the EURORDIS study is likely to have overestimated
the success rate given that it predicted over 120 approved
OMPs by the end of 2012, where in fact only 78 were ap-
proved by this time [4].
The price level and sales revenue for OMPs is import-
ant in determining the budget impact in future. The dis-
tribution of sales is skewed between OMPs, with a few
drugs accounting for a large share of aggregate budget
impact. The majority of OMPs have relatively low annual
sales. The success of some outlier OMPs, such as imatinib,
has contributed to an impression that OMPs consistently
achieve high sales. In reality, between 2000 and 2012, only
the top five selling OMPs in each market have reported
average sales per annum in excess of SEK 30 million in
Sweden and EUR 50 million in France [17,18].
It is possible that in future this situation might change.
For example, it has been suggested that the greater par-
ticipation of larger pharmaceutical manufacturers in the
OMP market might lead to higher prices and increased
volumes of sales, or changes in the political or payer
environment could further affect uptake. While this is
difficult to predict, sensitivity analysis suggested that an
increase in average OMP sales by 50% would almost
double the budget impact versus the base case. However
such a large increase in average OMPs sales must be
considered unlikely given the scrutiny that OMPs face
during pricing negotiations at product launch [3].
The price change of OMPs at loss of IPP is also uncertain
and important. It is too early in the history of European
Regulation to know how OMP prices will change once IPP
is lost. The impact of genericization on price is influenced
by many factors, including the size of the patient popula-
tion, the complexity of the manufacturing process, and the
number of generic manufacturers who enter the market
[28]. Imatinib, which accounted for 34% of total OMP sales
between 2000 and 2012 in Sweden, and for 27% of total
OMP sales in France [17,18], became subject to generic
competition in late 2013, with four generics being approved
in Europe [29]. While it is too early to know the effect this
will have on price, the extent of interest from generic man-
ufacturers is positive. The conservative assumption in the
sensitivity analysis that loss of IPP will have no impact on
price is unlikely [30]. Regardless, the results of the analysis
were not particularly sensitive to assumptions concerning
price change at loss of IPP.
Results from this analysis also match previous results by
from the European-wide budget impact assessment of
OMPs carried out by the same authors in 2011 [13]. Des-
pite a different modeling approach that used rare diseases
rather than OMPs as the primary forecasting unit, the pre-
vious analysis predicted a peak budget impact of 4.6% of
total European pharmaceutical expenditure, compared
with 4.1% in Sweden and 4.9% in France in the current
analysis. These findings support the structural validity of
the model and the assumptions used for this analysis.
The robustness of the forecasting model is further
supported by the comprehensive nature of the data used.
Average OMP sales were estimated using sales data from
each country for all OMPs approved in Europe since the
introduction of the OMP Regulation. Analyses on OMP
designations and marketing authorization approvals used
the cumulative history of such decisions since 2000, as
well as further validating these data with similar compar-
isons using the longer term more extensive and robust
US dataset.
Potential weaknesses in the model primarily relate to
those associated with forecasting assumptions. The suc-
cess rate for designated OMPs significantly affects the
likely budget impact, but can only be predicted based on
observed rates. These have changed over time, both in
Europe and in the US, and this analysis assumes a con-
stant and recent European trend rate. In reality, the US
experience suggests that the future trend might be lower,
meaning that assumptions for this analysis may be con-
servative. Furthermore, it is impossible to precisely esti-
mate how the denominator in the model – the growth
of the wider pharmaceutical market in both countries –
will evolve in the forthcoming years. Demographic
change is by itself likely to result in continued drug ex-
penditure growth in future. The 2% growth rate used in
the base-case is half the average growth rate observed in
the last 12 years (Figure 7), reflecting the lower GDP
growth in Europe. Sensitivity analyses confirmed that
the model was not sensitive to this parameter.
The base-case results from this model were implicitly
compared against the linear trend rate of the OMP
budget impacts from France and Sweden from 2000–
2012. The authors believe that the more sophisticated
modeling exercise conducted in this analysis has greater
validity because it incorporates additional available infor-
mation relating to future OMP designations, marketing
authorization approvals and price adjustments following
loss of IPP. Critically, given that all OMPs are covered
by a 10-year marketing exclusivity, a simple extrapola-
tion from the first decade of OMP experience in these
countries would neglect the impact of loss of IPP from
marketed OMPs.
Conclusions
The budget impact of OMPs in France and Sweden is ex-
pected to plateau between 4% and 5% of the total national
pharmaceutical market expenditure in 2020, and is there-
fore likely to remain sustainable and a small proportion of
total pharmaceutical expenditure, despite payer concerns
about growing designation rates. Expected sustainable
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expenditure growth reflects low success rates for OMP
marketing approval, and the impact of IPP expiries. This
analysis represents the most robust assessment to date of
the future budget impact of OMPs in France and Sweden.
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